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A B S T R A C T
Acute respiratory failure due to chronic obstructive pulmonary disease (COPD) presents an increasing problem
throughout the world. The aim of this study was to compare invasive and non-invasive mechanical ventilation (MV) for
patients with COPD. A prospective, randomized trial was performed in a multidisciplinary intensive care unit for the pe-
riod of 36 months and included 156 patients with COPD. MV procedure was performed using standard methods, and
was applied as either invasive MV (IMV) or noninvasive MV (NIMV). Patients were randomized in two groups for appli-
cation of MV using closed, nontransparent envelops. Comparison was made based on patient characteristics, objective
parameters on admission and 1h, 4h, 24h, and 48h after admission and based on treatment outcome. We have confirmed
that NIMV method is superior to IMV for patients with COPD. MV duration NIMV:IMV was 94:172 hours, p<0.001,
time spent in Intensive Care Unit 120:223 hours, p<0.001. Ventilator associated pneumonia 5(6%):29(37%), p<0.001.
The advantage of NIMV in COPD patients, especially in the early stages was confirmed.
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Introduction
Mechanical ventilation (MV) is mainly reserved for
late stages of Chronic obstructive pulmonary disease
(COPD) or in patients with rapid clinical deterioration1,2.
Applying the standard invasive mechanical ventilation
(IMV) means confronting the patient with the sideefects
and complications following endotracheal intubation, in-
cluding high ratio of Ventilator Associated Pneumonia
(VAP) and difficult weaning3,4. Furthermore, tracheal in-
jury caused by the endotracheal tube producing ulcer-
ation, oedema and haemorrhage are also frequently ob-
served during prolonged IMV5. Noninvasive mechanical
ventilation (NIMV) is increasingly been used as an alter-
native to conventional IMV through an endotracheal
tube, but mostly in the early stages of acute respiratory
failure (ARF), and in patients with a low Acute Physio-
logy and Chronic Health Evaluation II (APACHE II) and
Kelly – Matthay score6–8. It offers some advantages over
IMV, including improvied patient comfort and main-
tained airway defence mechanisms, speech and swallow-
ing without the use of an endotracheal tube9,10. Unfortu-
nately, potential complications like damage to the facial
and nasal skin, higher incidence of gastric distension
with aspiration risk, sleeping disorders and conjuctivitis
can occure during the course of NIMV11. Furthermore,
conditions like coma, schock and cardiorespiratory ar-
rest, swallowing disorders mental immaturity, face defor-
mations and unstabile respiratory centre present abso-
lute contraindications for this MV method. There are
still many disagreements and dillemmas on when and
how to apply NIMV. Advantage of either MV method has
not yet been confirmed by neither clinical nor laboratory
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parameters. Based on all of the above, the goal of our
study was to determine the relationship and influence of
objective parameters of pulmonary mechanics and bio-
chemistry on the choice of MV method and tretment out-
come in patients with COPD. Furthermore, to confirm
the advantage of the specific MV method in COPD pa-
tients based on the treatment outcome of the specific MV
method – MV duration, time spent in Intensive Care
Unit (ICU) and incidence of VAP.
Patients and Methods
A prospective randomized trial was carried out in our
ICU at General Hospital »Dr. Josip Ben~evi}« in Slavon-
ski Brod, Croatia during 36 months. The study included
156 patients with COPD that fulfilled the inclusion and
didn’t have the exclusion criteria, that were as follows –
expected MV duration shorter than 24h, use of MV on
admission to the ICU, patients in coma and those who
had cardio-respiratory arrest within 5 days, patients in
shock, patients with unstable respiratory centre, those
scheduled for organ donation and patients that were ad-
mitted to the ICU because of the ARF due to COPD
within 3 months.
These patients were than randomized for either NIMV
or IMV using closed, nontransparent envelops each con-
taining information on one of the methods investigated.
After a patient was included in the study, a third party
not involved in the study was asked to choose one of the
envelopes. Depending on the information in the chosen
envelope, the patient was allocated to either NIMV or
IMV method.
Following patient data were collected on admission:
sex, age, comorbidities (hypertension, diabetes mellitus,
and congestive heart disease) and previous use of MV.
Severity of illness was assessed using APACHE II
score both on admission and during MV procedure. In
APACHE II score, value of 20 is set as statisticaly impor-
tant for survival rate, because if APACHE II score is un-
der 20 mortality rate is about 20%, and above 20 mortal-
ity rate rises to 40% and more12.
Objective patient data were measured and recorded
on admission to the ICU, 1h, 4h, 24h and 48h after ad-
mission. After that, every 24h of ICU stay, and if neces-
sary more often than that. Following objective data were
measured and recorded during MV procedure: respira-
tory rate (RR), tidal volume (Vt), arterial blood oxygen
saturation (SatO2), negative logarithm of H
+ concentra-
tion (pH), partial pressure of arterial oxygen (PaO2), par-
tial pressure of arterial carbon dioxide (PaCO2) and bi-
carbonate blood level, arterial oxygen tension/inspiratory
oxygen fraction (PaO2/FiO2 ratio), RR/Vt ratio, maximal
inspiratory pressure (Pimax), plato inspiratory pressure
(Pplato), airway resistance (R) and static pulmonary
compliance (Cst).
Following objective parameters were used as indica-
tions for the application of one of MV methods: worsen-
ing of clinical status, spontaneous RR>30/min, sponta-
neous Vt<5 ml/kg, PaO2<60 mmHg, PaCO2>55 mmHg,
pH<7.30, SatO2<88%, PaO2/FiO2<200, RR/Vt>100, re-
stless patient.
During the research, following data were also col-
lected for each MV method: total MV duration, length of
ICU stay, success of MV, need for tracheotomy, incidence
of VAP and ICU mortality.
Furthermore, in NIMV patients, need for intubation
was recorded, but since all patients in IMV group are
intubated, this parameter was not statistically evaluated.
Need for tracheostomy was assesed using evidence-
-based guidelines for weaning and discontinuing venti-
latory support which recomend to consider a tracheo-
stomy for patients after an initial period of stabilization
on the ventilator when it becomes apparent that the pa-
tient will require prolonged ventilatory assistance. Acor-
ding to these guidelines, a tracheostomy should than be
performed for the following patients: those requiring
high levels of sedation to tolerate translaringeal tubes,
those with marginal respiratory mechanics in whom a
tracheostomy tube having lover resistance might reduce
the risk of muscle overload, those who may develop psy-
chological benefit from the ability to eat orally, communi-
cate by articulated speech, and experience enhanced mo-
bility, and those in whom enhanced mobility may assist
physical therapy efforts.
VAP was identified based on the algorithm of clinical
pulmonary infection score (CPIS). This algorithm con-
sists of 6 parameters: radiographic image showing new
infiltration, body temperature >38.5°C, leukocytosis over
10000 (mm3)–1, purulent tracheal secretion, respiratory
index PaO2/FiO2<200 and absence of other infection
source.
NIMV and IMV were compared based on the statisti-
cally determined difference in objective parameters and
MV treatment outcome. Based on these results the ad-
vantage of one of the methods was established. During
ICU stay, patients received all necessary treatment re-
quired by their condition. All laboratory and clinical pa-
rameters were evaluated and corrected if necessary. En-
teric nutrition was preferred to parenteral whenever
possible, applied through nasogastric tube or peroraly.
For patients with a nasogastric tube, a seal connector in
the dome of the mask was used to minimize air leakage.
Disconnection from NIMV was allowed for less than 1h
to permit eating, drinking and expectoration. During
these intervals, oxygen supplementation was delivered
via a nasal canula to keep oxygen saturation at 90% as
measured by pulse-oximetry.
IMV protocol
Patient with respiratory insufficiency, who had IMV
applied, was orotrachealy intubated. During IMV pa-
tients received the lowest respiratory support level that
secured SatO2>90% with FiO20.6, satisfying CO2 elimi-
nation (PaCO245 mmHg) and stabile hemodynamic pa-
tient condition. Weaning process was conducted using
pressure support ventilation (PSV). Initial positive pres-
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sure support was 18 cmH2O. This support was than re-
duced by 2–4 cmH2O depending on the patients clinical
status and values of the measured parameters of pulmo-
nary mechanics, biochemistry and circulation. Patients
were extubated at pressure support of 5 cmH2O which
was necessary to overcome increased airway resistance
(existing due to lowering airway diameter by an endo-
tracheal tube). After weaning process was concluded,
continuous patient monitoring was performed, side ef-
fects and complications as well as need for further MV
were observed and evaluated. Patients were continu-
ously monitored until they were either dismissed from
ICU, or death occurred.
NIMV protocol
Patient’s head-pad was raised to 45°, necessary equip-
ment was prepared next to patient’s head and the proce-
dure that follows was explained. Appropriate facemask
was chosen and connected to the ventilator. Ventilator
parameters were set to: continuous positive air pressure
(CPAP) to 0 cmH2O, PSV 10 cmH2O and FiO2 was ad-
justed to reach SatO2>90%. The nose was protected us-
ing strapping to prevent skin damage. Patient was cal-
med down and the mask was held gently applied to the
patient’s face simultaneously trying to harmonize pa-
tient’s respiration with the ventilator. Next step was to
secure the firmmask positioning using head stripes. Ven-
tilator was than set to CPAP 3–5 cmH2O and PSV 10–25
cmH2O in order to reach Vt>5 ml/kg and RR<30/min.
After that, the alarms on the ventilator and respiratory
support level were set. Right communication with the pa-
tient was ensured, and the patient was explained how to
signalize if in need of help or in case of complications oc-
currence.
According to patient’s state development, clinical sta-
tus and objective parameters, ventilatory support level
was reduced until MV could be discontinuated. NIMV
failure was defined as mandatory need for endotracheal
intubation. This was performed in the case of respiratory
arrest, loss of consciousness, severe psychomotorical agita-
tion that requires sedation, hemodynamic instability,
failure to reach SatO2>90%with FiO20.6 and PaCO2>60
mmHg. For both methods MV was considered to be suc-
cessful if the patient remained in spontaneous respira-
tion for at least 48 h after the withdrawal of MV.
In all patients included in the research, MV was ad-
ministered by use of Evita Drager dura 2 ventilators
(Dräger, Lubeck, Germany), with software option for
NIMV and Puritan Bennet 7200 ventilators (Puritan
Bennet, Carlsbad, CA, USA). Nasal and facemasks were
applied for NIMV (Respironics Inc, Herrsching, Ger-
many). Parameters of pulmonary mechanics were di-
rectly measured on the ventilator. For patients with
spontaneous breathing, tidal volume and respiratory fre-
quency were measured using Spiro meter (Ohmeda Biox,
Louisville, CO, USA), a maximal inspiratory pressure,
using manometer (Ohmeda Biox). Arterial blood gas
analysis was performed on Ciba Corning Blood Gas Ma-
chine (Ciba Corning, Halsted, England). Cardio-respira-
tory functions were continuously monitored using Datex
monitors (Datex Ohmeda, Helsinki, Finland), and venti-
lation and oxygenation using Datex Engstrom AS3 and
CS3 Compact (Datex Ohmeda, Helsinki, Finland).
Statistical analysis
Qualitative and numerical data were analyzed with
descriptive statistic parameters: median, minimum va-
lue, maximum value, interquartile (IQ) range. Frequen-
cy tables were used to present qualitative data. Contin-
gency tables with c2-test were employed for comparison
of two independent for qualitative variables. In case of
small sample size, Fishers exact test was used. Mann-
-Whitney test was employed for the comparison of two in-
dependent groups on numerical data. Normality of dis-
tribution was tested by the Kolmogorow-Smirnov test.
p<0.01 was considered statistically significant. The sta-
tistical analysis was performed using the SPSS statistical
software package for Windows (Release 9.0, Standard
version, SPSS Inc., Chicago, IL, USA). The study aimed
to recruit 156 patients divided in two groups to ensure
the detection of a 20% difference between the choices of
MV method of the two groups with a power of 80%.
The study was carried out in line with ethical princip-
les and was approved by the Hospital Ethics Committee.
No author has a conflict of interest in regard of de-
vices discussed in this publication. Support was provided
from institutional and departmental sources.
Results
The results of the study are presented through one
figure and four tables.
A flow chart shows flow of patients through the study
(Figure 1).
The results of this research have shown that both
NIMV and IMV are suitable methods for securing respi-
ratory support for COPD patients with ARF. Comparison
of NIMV and IMV for patients with COPD based on
study population characteristics is presented (Table 1).
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COPD patients included
in the research
n=156
randomization
IMV
n=78
NIMV
n=78
Success
n=48(61%)
Failure
n=30(39%)
Success
n=38(49%)
Failure
n=40(51%)
Fig. 1. Flow of patients through the study, ICU – Intensive Care
Unit, IMV – Invasive Mechanical Ventilation, NIMV- Nonin-
vasive Mechanical Ventilation, COPD – Chronic Obstructive
Pulmonary Disease, VAP – Ventilator Associated Pneumonia,
n – number of patients.
Furthermore, comparison of NIMV and IMV based on
parameters of pulmonary mechanics is presented (Table
2). Comparing NIMV vs. IMV based on the parameters
of pulmonary mechanics during the first 48h, an in-
crease in Vt and a decrease in respiratory frequency
were observed in the NIMV group, and in IMV group,
these parameters were preset and constant (p<0.001).
Pimax values were high in both groups but significantly
lower in NIMV group (28–19:45–28, p<0.001). Also, air-
way resistance was significantly lower in NIMV group
(16–10:23–16 cmH2O, p<0.001), and Cst was higher
(0.031–0.037:0.021–0.026), p=0.100–0.057) with statisti-
cally significant improvement in the first 48h in both
groups. Airway resistance was significantly higher in
IMV group because all patients were intubated. Com-
parison of NIMV and IMV based on pulmonary bio-
chemistry parameters (Table 3). Comparing NIMV vs.
IMV group based on the parameters of pulmonary bio-
chemistry during the first 48h, pH value improvement
was observed in both groups (7.26–7.37; 7.28–7.37,
p=0.216–0.456). A significant improvement was also ob-
served in PaO2 values in both groups without statisti-
cally significant difference in favour of either group
(68–84:70–90, p=0.325–0–245). Similar results were in
values of PaCO2 (77–52:70–48, p=0.047–0.248). Also, an
improvement in SatO2 in the first 48h was recorded,
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TABLE 1
COMPARISON OF NIMV AND IMV FOR PATIENTS WITH COPD BASED ON STUDY POPULATION CHARACTERISTICS
Study population characteristics
MV method
p
NIMV n=78 IMV n=78
Age (years)
Median; IQ range (min-max)
58; 13
(35–82)
54; 12
(38–78)
0.805
APACHE II
Median; IQ range (min-max)
24; 4
(18–34)
23; 3
(18–34)
0.687
Sex n (%)
Male 53 (68) 50 (64) 0.608
Female 25 (32) 28 (36) 0.656
Co-morbidities n (%)
Hypertension 31 (40) 29 (37) 0.654
Diabetes Mellitus 10 (13) 12 (15) 0.636
Heart disease 25 (33) 22 (28) 0.490
Prior MV application n (%) 29 (37) 33 (42) 0.505
APACHE – Acute Physiology and Chronic Health Evaluation, MV – mechanical ventilation, NIMV – noninvasive mechanical ventila-
tion, IMV – invasive mechanical ventilation, n – number of patients, p – statistical difference between groups
TABLE 2
COMPARISON OF NIMV AND IMV BASED ON PARAMETERS OF PULMONARY MECHANICS
Parameters of pulmonary
mechanics
Vt
(mL)
RR
(nmin–1)
RR/Vt
(n min–1 L–1)
Pimax
(mmHg)
Pplato
(mmHg)
R
(cmH2O L–1 s–1)
Cst
(L cmH2O–1)
1h
NIMV 320(55) 25(11) 80(39) 28(11) 23(7) 16(5) 0.031(0.015)
IMV 500(70) 13(1) 26(6) 45(12) 40(7) 23(7) 0.021(0.005)
p <0.001 <0.001 <0.001 <0.001 <0.001 0.003 0.100
4h
NIMV 340(50) 22(10) 64(40) 25(8) 20(6) 12(4) 0.034(0.018)
IMV 500(70) 13(1) 26(6) 37(13) 32(11) 19(5) 0.026(0.008)
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.078
24h
NIMV 380(70) 19(11) 49(42) 25(7) 22(5) 10(3) 0.037(0.014)
IMV 480(90) 10(2) 21(10) 35(9) 33(7) 17(8) 0.026(0.008)
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.093
48h
NIMV 420(80) 15(11) 35(30) 19(7) 17(4) 10(3) 0.037(0.014)
IMV 480(60) 10(2) 21(8) 28(9) 25(9) 16(5) 0.026(0.010)
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.057
– all data are presented as median (IQ range)
p – statistical difference between groups, Vt – tidal volume, RR – respiratory rate, Pimax – maximal inspiratory pressure, Pplato –
plato pressure, R – airway resistance, Cst – static pulmonary compliance, NIMV – noninvasive mechanical ventilation, IMV – invasive
mechanical ventilation
without statistically significant difference in favour of
either group (84–92:88–94, p=0.134–0.261). There was
no statistical difference in bicarbonate values.
Moreover, comparison of NIMV and IMV for patients
with COPD based on treatment outcome is presented
(Table 4). In our research, statistically significant advan-
tage in favour of NIMV was in MV duration – median
94:172 h (p<0.001), time spent in ICU – median 120:223
h (p<0.001). VAP was recorded in only 5(6%) patients in
NIMV group and in 29(37%) patients with IMV (p<0.001).
Furthermore, 5(6%) patients in NIMV group needed tra-
cheotomy, vs. 27(35%) patients in IMV group (p<0.001).
Despite these differences, no statistically significant dif-
ference in procedure success between NIMV and IMV
group was recorded (p=0.925). Although the IMV group
had faster correction of parameters of pulmonary bio-
chemistry, they had longer MV duration and total ICU
stay, mostly because of the prolonged weaning proce-
dures.
Discussion
We found that NIMV significantly reduces the need
for endotracheal intubation and shortens the duration of
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TABLE 3
COMPARISON OF NIMV AND IMV BASED ON PULMONARY BIOCHEMISTRY PARAMETERS
Parameters of pulmo-
nary biochemistry
pH PaO2 (cmH2O) PaCO2 (cmH2O) PaO2/FiO2
Bicarbonates
(mmol L–1)
SatO2 (%)
0h
NIMV 7.21(0.09) 66 (15) 84 (18) 110 (50) 27 (7) 80 (9)
IMV 7.22(0.07) 66 (12) 83 (16) 109 (48) 28 (9) 79 (9)
p 0.778 0.910 0.687 0.890 0.980 0.875
1h
NIMV 7.26(0.08) 68 (13) 77 (13) 113 (45) 27 (7) 84 (7)
IMV 7.28(0.08) 70 (15) 70 (14) 116 (31) 28 (9) 88 (8)
p 0.216 0.325 0.047 0.317 0.868 0.134
4h
NIMV 7.29(0.08) 72 (13) 69 (17) 144 (64) 28 (8) 88 (7)
IMV 7.35(0.11) 80 (12) 55 (14) 160 (45) 26 (10) 90 (3)
p 0.023 0.156 <0.001 0.021 0.555 0.228
24h
NIMV 7.35(0.10) 80 (12) 60 (18) 200 (66) 27 (6) 91 (7)
IMV 7.38(0.06) 85 (15) 52 (11) 212 (57) 26 (9) 93 (3)
p 0.120 0.234 0.015 0.043 0.899 0.285
48h
NIMV 7.37(0.09) 84 (11) 52 (10) 210 (98) 25 (5) 92 (7)
IMV 7.37(0.05) 90 (13) 48 (9) 225 (68) 26 (6) 94 (3)
p 0.456 0.245 0.248 0.003 0.911 0.261
– all data are presented as median (IQ range)
pH – negative logarithm of H+ concentration, PaO2 – partial arterial oxygen pressure, PaCO2 – partial arterial carbon dioxide pressure,
FiO2 – fraction of inspired oxygen, SatO2 – arterial oxygen saturation, NIMV – noninvasive mechanical ventilation, IMV – invasive me-
chanical ventilation, p – statistical difference between groups
TABLE 4
COMPARISON OF NIMV AND IMV FOR PATIENTS WITH COPD BASED ON TREATMENT OUTCOME
MV treatment outcome
MV method
pNIMV
n=78
IMV
n=78
MV duration (hours)
Median IQ range (min-max)
94; 26
(55–211)
172; 50
(105–425)
<0.001
Time spent in ICU (hours)
Median IQ range (min-max)
120; 22
(86–280)
223; 60
(144–576)
<0.001
Successful treatment n (%) 48 (61) 38 (49) 0.316
VAP n (%) 5 (6) 29 (37) <0.001
Tracheotomy n (%) 5 (6) 27 (35) <0.001
ICU-mortality n (%) 4 (5) 5 (6) 0.925
MV –mechanical ventilation, NIMV – noninvasive mechanical ventilation, IMV – invasive mechanical ventilation, VAP – ventilator as-
sociated pneumonia, ICU – Intensive Care Unit, n – number of patients, p – statistical difference between groups
MV support. Furthermore, it reduces the time spent in
the ICU, leading to cost reduction and increased number
of ICU beds available for other patients. This is par-
ticulary important for multidisciplinary ICUs like ours,
since it is, for example, the only fully equipped ICU in
our hospital and always has a shortage of beds.
Kramer et al.13 in their research in 1995 reported that
a success ratio of 74% when using NIMV in COPD pa-
tients with fast blood gas exchange improvement and the
posibility to avoid endotracheal intubation. Therefore,
they reported this method as a method of choice in COPD
patients.
Brochard et al.14 in a multicentric study from 1995,
conducted on 85 COPD patients with ARF (pH 7.270.1,
PaCO2 7012 cmH2O), report rapid improvement in
PaO2, and slower correction of PaCO2. Patients randomi-
zed for NIMV had significantly lower intubation ratio.
They reported lower complications ratio (14%:45%,
p<0.001) and reducedmortality rate with NIMV (9%:29%,
p=0.02), as well as shorter hospital treatment duration
(2317:3533 days, p=0.02). Even so, they questioned
the NIMVs’ ability to replace IMV in patients with COPD
because only 29% of such patients are suitable for NIMV.
They therefore concluded that NIMV can only be re-
searched as an alternative procedure to IMV, and not as a
comparable and competitive method.
Futhermore, in the same year, Jones et al.15 reported
that NIMV is suitable as a first line intervention in care-
fully chosen patients with COPD facing ARF. They re-
ported that COPD patients with pneumonia and conges-
tive heart failure are not suitable for this MV method.
In 1998., Guerin et al.16 reported that 39% of patients
with COPD that had NIMV applied eventually had to be
endotracheally intubated which was similar to the re-
sults of Brochard et al.
Robino et al.17 in their study in 2003 researched the
success of NIMV in opposite of patients with decom-
pensated chronic obstructive and restrictive pulmonary
diseases. The research was conducted on 64 patients
with COPD and 20 with chronic restrictive pulmonary
disease. In the group of patients with chronic restrictive
pulmonary disease, number of patients with successful
NIMV was smaller compared to COPD group, and need
for endotracheal intubation was higher (67:35%, p=0.01).
After 12h of NIMV application, similar results were ob-
served for respiratory frequency, minute volume and ar-
terial blood gases. pH and PaCO2 improvement after 12h
was better in COPD patients and they report this a pre-
dictor of success, but that isn’t the case with restrictive
pulmonary disease patients. Success of NIMV in ARF is
therefore lower in chronic restrictive pulmonary dis-
eases.
The incidence of VAP in our study was significantly
lower in the NIMV group which is consistent with the re-
cently published paper by Scala et al.18, although these
authors only included patients with moderate to severe
hypercapnic encephalopathy, defined by the Kelly score
of 3 or higher. Opposite to the study of Scala et al., the re-
sults in our study also showed a reduced need for tra-
cheostomy in favour of NIMV group, which was mainly
related to the higher initial success rate with NIMV and
reduced MV duration.
Similar results presented Keenan et al.19 in their
study in 2003. They confirmed the advantage of NIMV as
a method that, compared to IMV in patients with acute
exacerbation of COPD, reduces the need for endotracheal
intubation to 28%, reduces mortality rate from 15% to
10% and MV duration from 6.83 to 4.57 days.
Opposite to these results, Squdrone et al.20 in their re-
search from 2004, had high failure ratio with NIMV ap-
plied in acute exacerbations of COPD. They had to in-
tubate 40 of 64 patients. MV duration, mortality rate and
treatment duration were similar in both groups. When
NIMV was successful, complication incidence and mor-
tality rate were lower and treatment duration was shor-
ter, but NIMV procedure overall had high failure ratio,
and those patients, who failed NIMV had worse end-out-
come results than patients who were treated with IMV
from the beginning.
ICU mortality rates were similar in both groups. This
shows that although NIMV offers many advantages in
COPD patients requiring ventilatory support, mortality
rates are also dependent on other factors including age,
APACHE II score on ICU admission, concomitant dis-
eases etc.
Our study has several limitations. Although it in-
cludes a large number of COPD patients, we must point
out that some of the patients were admitted more than
once, but were included in the study if at least 3 months
had passed since last admission. In such cases, patients
were considered as »new« and were enrolled in the study.
Furthermore, our study lacks the follow-up on patients
after they were discharged from the ICU and therefore
we could not record the in-hospital mortality rates. Fi-
nally, NIMV has not yet become an extensive part of rou-
tine practice in our hospital, although the number of
physicians using it is increasing.
In conclusion, we can say that the advantage of NIMV
in COPD patients, especially in the early stages was con-
firmed.
R E F E R E N C E S
1. KONDILI E, ALEXOPOULOU C, PRINIANAKIS G, XIROUCHA-
KI N, GEORGOPOULOS D, Intensive Care Med, 30 (2004) 1311. — 2.
PAUWELS RA, BUIST AS, CALVERLEY P, Am J Respir Crit Care Med,
163 (2001) 1256. — 3. NEVINSML, EPSTEIN SK, Chest, 119 (2001) 1840.
— 4. LUYT CE, CHASTRE J, FAGON JY, Intensive Care Med, 30 (2004)
844. — 5. CONTI G, ANTONELLI N, NAVALESI P, Intensive Care Med,
28 (2002) 1701. — 6. ELLIOT MW, Intensive Care Med, 28 (2002) 1691.
— 7. BROCHARD L, Thorax, 55 (2000) 817. — 8. KELLY BJ, MATTHAY
HD, Chest, 104 (1993) 1818. — 9. GORINI M, GINANNI R, VILLELLA
G, TOZZI D, AUGUSTYNEN A, CORRADO A, Intensive Care Med, 30
(2004) 875. — 10. BROCHARD L, Eur Respir J, 22 Suppl. 47 (2003) 31. —
11. GIRAULT C, BRIEL A, HELLOT MF, TAMION F, WOINET D, LE-
M. Jurjevi} et al.: COPD and Mechanical Ventilation, Coll. Antropol. 33 (2009) 3: 791–797
796
SOY S, Crit Care Med, 31(2) (2003) 552. — 12. KNAUS WA, DRAPER
EA, WAGNER DP, ZIMMERMAN JE, Crit Care Med,13 (1985) 818. — 13.
KRAMER N, MEYER TJ, MEHARG J, Am J Respir Crit Care Med, 151
(1995) 1799. — 14. BROCHARD L, MANCEBO J, WYSOCKIM, LOFASO
F, CONTI G, RAUSS A, N Engl J Med, 333 (1995) 817. — 15. JONES DJ,
PAUL EA, JONES PW, Am J Respir Crit Care Med, 152 (1995) 538. — 16.
GUERIN C, GIRARD R, CHEMORIN C, DE VARAX R, FOURNIER G,
Intensive Care Med, 24 (1998) 1024. — 17. ROBINO C, FAISY C, DIEHL
JL, REZGUIN, LABROUSSE J, GUEROTE, Intensive CareMed, 29 (2003)
603. — 18. SCALA R, NAVA S, CONTI G, ANTONELLI M, NALDI M,
ARCHINUCCI I, Intensive Care Med, 33 (2007) 2101. — 19. KEENAN
SP, SINUFF T, COOK DJ, HILL NS, Annals of Internal Medicine, 138(11)
(2003) 861. — 20. SQUADRONE E, FRIGERIO P, FOGLIATI C, GRE-
GORETI C, CONTI G, ANTONELLI M, Intensive Care Med, 30 (2004)
1303.
M. Jurjevi}
Department of Anaesthesiology and Intensive Care, General Hospital »Dr. Josip Ben~evi}«, A. [tampara 42,
35000 Slavonski Brod, Croatia
e-mail: mtjurjevic@yahoo.com
USPOREDBA NEINVAZIVNE I INVAZIVNE UMJETNE VENTILACIJE KOD BOLESNIKA S
KRONI^NOM OPSTRUKTIVNOM PLU]NOM BOLESTI; PROSPEKTIVNA RANDOMIZIRANA
STUDIJA
S A @ E T A K
Akutno respiratorno zatajenje uzrokovano kroni~nom opstruktivnom plu}nom bolesti (KOPB) predstavlja rastu}i
problem {irom svijeta. Cilj ove studije bila je usporedba invazivne i neinvazivne umjetne ventilacije (UV) kod bolesnika
sa KOPB. Ova prospektivna, randomizirana studija je trajala 36 mjeseci i provedena je u multidisciplinarnoj jedinici
intenzivnog lije~enja. Uklju~ivala je 156 bolesnika sa KOPB. UV je provo|ena primjenom standardnih metoda, a pri-
mjenjivana je kao invazivna UV (IUV) ili neinvazivna UV (NIUV). Bolesnici su randomizirani u dvije skupine za pri-
mjenu UV kori{tenjem zatvorenih, neprozirnih omotnica. Usporedba je provedena na osnovi karakteristika bolesnika,
objektivnih parametara kod prijema, 1h, 4h, 24h i 48h nakon prijema te na osnovi parametara ishoda lije~enja. Istra-
`ivanje je potvrdilo prednost NIUV u odnosu na IUV kod bolesnika sa KOPB. Trajanje UV NIUV:IUV bilo je 94:172h,
p<0,001, vrijeme provedeno u jedinici intenzivnog lije~enja 120:223h, p<0,001. Pojavnost ventilator udru`ene pneu-
monije bila je 5(6%):29(37%), p<0,001. Potvr|ena je prednost NIUV kod KOPB bolesnika, osobito u ranijim stadijima
bolesti.
M. Jurjevi} et al.: COPD and Mechanical Ventilation, Coll. Antropol. 33 (2009) 3: 791–797
797
